Divyaswathi Citla Sridhar: We Counsel Patients With Obesity About VTE Risk, But What Does Real-World Data Actually Show?
Divyaswathi Citla Sridhar, a pediatric hematologist and oncologist at Arkansas Children’s Hospital, shared a post on LinkedIn:
“We counsel patients with obesity about VTE risk—but what does real-world data actually show?
Our new study published in RPTH Journal analyzed >4 million females prescribed hormonal therapy and found:
• Higher VTE rates with several ethinyl-estradiol–containing therapies in obese users
• No significant VTE increase with progesterone-only therapy
Title: Venous thromboembolism in obese hormonal contraceptive users: a large national database study
Authors: Divyaswathi Citla-Sridhar, Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel P. Rosovsky, Nancy Sokkary.
Grateful to work with a fantastic group of collaborators: Madhvi Rajpurkar Lakshmi Srivaths Bethany Samuelson Bannow Rachel Rosovsky Nancy Sokkary & Foundation for Women & Girls With Blood Disorders.”
Learn more with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis